Skip to main content

Current Advances in Psychedelic Medicine in the Treatment of Substance Use Disorders

Sponsored By:

This webinar will include a general overview of psychedelics and their current use to treat substance use disorders, and will also include a brief outline of the first, second and third wave of the psychedelic revolution.

Despite the growing evidence of their therapeutic benefit for various conditions, classifying psychedelics as a Schedule 1 drug (defined as drugs of abuse with no therapeutic benefits) has severely hampered research on their use in the treatment of Substance Use Disorders. Based on the current, various controlled studies demonstrating their effectiveness, there is a strong case to be made that rescheduling psychedelics drugs would advance therapeutic research. When incorporated thoughtfully into treatment, psychedelics have the potential to reshape biological approaches in the treatment of substance use disorders and related psychiatric conditions such as depression and post-traumatic stress disorder.

Substances to be covered in this webinar include LSD and the treatment of alcoholism, MDMA-assisted psychotherapy for severe post-traumatic stress disorder, Ketamine for refractory depression, Psilocybin (mushrooms) for the treatment of despair and hopelessness in addictive disease in death and dying patients, Ayahuasca (leaves and bark) for the treatment of opiate addiction and major depressive disorders, Ibogaine (from toad secretions) for the treatment of opioid dependence, Peyote for the treatment of alcoholism and use in Native American rituals, and medical cannabis and CBD for the treatment of pain and substance use disorder.

Upon completion of this webinar, attendees will know more about:

  • Brief history of the use of psychedelics during the first, second, and third psychedelic revolutions.
  • Understanding of the different psychedelic substances and their therapeutic effects.
  • Today’s research and the barriers to that research due to their Schedule 1 classification and current antiquated attitudes towards psychedelics as effective therapy tools.
Back to Top